Last reviewed 2026-04-20 · How we verify

Bametan (BAMETHAN)

Phase 2 active Small molecule

Bametan (generic name: BAMETHAN) is a bamethan drug. It is currently in Phase 2 development.

Bametan is thought to work by interacting with a specific molecular target to produce its therapeutic effects.

Bametan (BAMETHAN) is a small molecule drug in the bamethan class, but specific details about its target, indications, and pharmacokinetics are unknown. Its commercial status, including patent status and generic availability, is also unclear. As a result, there is limited information available about its use in clinical practice. Bametan's mechanism of action and safety profile are not well-documented. Further research is needed to fully understand its potential benefits and risks.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BAMETHAN
Drug class	bamethan
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and the key to unlocking the right response is a specific molecule. Bametan is designed to fit into this lock, allowing the cell to respond in a way that treats the underlying condition. This is a simplified explanation of how bamethan drugs like Bametan are thought to work.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bametan CI brief — competitive landscape report
Bametan updates RSS · CI watch RSS

Frequently asked questions about Bametan

What is Bametan?

Bametan (BAMETHAN) is a bamethan drug.

How does Bametan work?

Bametan is thought to work by interacting with a specific molecular target to produce its therapeutic effects.

What is the generic name of Bametan?

BAMETHAN is the generic (nonproprietary) name of Bametan.

What drug class is Bametan in?

Bametan belongs to the bamethan class. See all bamethan drugs at /class/bamethan.

What development phase is Bametan in?

Bametan is in Phase 2.

Drug class: All bamethan drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing